Tag: intravenous iron drugs market analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Intravenous Iron Drugs Market Growth Potential: How Will Market Size Shift Through 2030?

The market for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to expand from $3.81 billion in 2025 to $4.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical rise in this market can be linked to the significant prevalence of iron deficiency anemia, challenges associated with oral iron absorption, structured hospital protocols for anemia management, increased adoption in dialysis centers, and the demonstrated clinical efficacy of IV iron therapies.

The intravenous iron drugs market size is expected to experience significant growth in the upcoming years. It is projected to reach $6.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during this period is attributable to the rising burden of chronic diseases, an expanding population of dialysis patients, an increase in cancer-related anemia cases, the demand for rapid hemoglobin correction, and the broadening of outpatient infusion services. Key trends for the forecast period include an increasing application in the management of iron deficiency anemia, a growing adoption among patients with chronic kidney disease, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and higher utilization in oncology and gastroenterology.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=95513183&type=smp&name=Intravenous%20Iron%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of chronic kidney disease (CKD) is projected to propel the expansion of the intravenous iron drugs market moving forward. Chronic kidney disease (CKD) signifies the progressive deterioration of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is attributed to escalating rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs aid chronic kidney disease patients by replenishing iron stores, rectifying anemia, and enhancing hemoglobin levels, which in turn improves oxygen transport and lessens the requirement for erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs market.

Intravenous Iron Drugs Market Segment Breakdown: Which Categories Lead On Revenue?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Intravenous Iron Drugs Market Trends Powering Strategic Industry Growth

Leading companies active in the intravenous iron drugs market are prioritizing the creation of novel therapies, such as intravenous (IV) iron replacement therapy, to enhance effectiveness, safety, and patient outcomes. Intravenous (IV) iron replacement therapy functions as a medical procedure that delivers iron directly into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly beneficial for patients who struggle to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical entity specializing in advanced drug development and healthcare provisions, declared that the U.S. Food and Drug Administration (FDA) had sanctioned Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients suffering from heart failure classified as New York Heart Association class II/III, with the aim of boosting exercise capacity. Injectafer is a broadly applied intravenous iron treatment, noted for its rapid replenishment of iron levels in individuals who are intolerant to or do not respond well to oral iron supplements.

Intravenous Iron Drugs Market Leading Players And Competitive Positioning

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

View The Full Intravenous Iron Drugs Market Report:

https://thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Intravenous Iron Drugs Market Growth Potential: How Will Market Size Shift Through 2030?

The market for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to expand from $3.81 billion in 2025 to $4.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical rise in this market can be linked to the significant prevalence of iron deficiency anemia, challenges associated with oral iron absorption, structured hospital protocols for anemia management, increased adoption in dialysis centers, and the demonstrated clinical efficacy of IV iron therapies.

The intravenous iron drugs market size is expected to experience significant growth in the upcoming years. It is projected to reach $6.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during this period is attributable to the rising burden of chronic diseases, an expanding population of dialysis patients, an increase in cancer-related anemia cases, the demand for rapid hemoglobin correction, and the broadening of outpatient infusion services. Key trends for the forecast period include an increasing application in the management of iron deficiency anemia, a growing adoption among patients with chronic kidney disease, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and higher utilization in oncology and gastroenterology.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=95513183&type=smp&name=Intravenous%20Iron%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of chronic kidney disease (CKD) is projected to propel the expansion of the intravenous iron drugs market moving forward. Chronic kidney disease (CKD) signifies the progressive deterioration of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is attributed to escalating rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs aid chronic kidney disease patients by replenishing iron stores, rectifying anemia, and enhancing hemoglobin levels, which in turn improves oxygen transport and lessens the requirement for erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs market.

Intravenous Iron Drugs Market Segment Breakdown: Which Categories Lead On Revenue?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Intravenous Iron Drugs Market Trends Powering Strategic Industry Growth

Leading companies active in the intravenous iron drugs market are prioritizing the creation of novel therapies, such as intravenous (IV) iron replacement therapy, to enhance effectiveness, safety, and patient outcomes. Intravenous (IV) iron replacement therapy functions as a medical procedure that delivers iron directly into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly beneficial for patients who struggle to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical entity specializing in advanced drug development and healthcare provisions, declared that the U.S. Food and Drug Administration (FDA) had sanctioned Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients suffering from heart failure classified as New York Heart Association class II/III, with the aim of boosting exercise capacity. Injectafer is a broadly applied intravenous iron treatment, noted for its rapid replenishment of iron levels in individuals who are intolerant to or do not respond well to oral iron supplements.

Intravenous Iron Drugs Market Leading Players And Competitive Positioning

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

View The Full Intravenous Iron Drugs Market Report:

https://thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Intravenous Iron Drugs Market Growth Potential: How Will Market Size Shift Through 2030?

The market for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to expand from $3.81 billion in 2025 to $4.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical rise in this market can be linked to the significant prevalence of iron deficiency anemia, challenges associated with oral iron absorption, structured hospital protocols for anemia management, increased adoption in dialysis centers, and the demonstrated clinical efficacy of IV iron therapies.

The intravenous iron drugs market size is expected to experience significant growth in the upcoming years. It is projected to reach $6.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. The anticipated growth during this period is attributable to the rising burden of chronic diseases, an expanding population of dialysis patients, an increase in cancer-related anemia cases, the demand for rapid hemoglobin correction, and the broadening of outpatient infusion services. Key trends for the forecast period include an increasing application in the management of iron deficiency anemia, a growing adoption among patients with chronic kidney disease, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and higher utilization in oncology and gastroenterology.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=95513183&type=smp&name=Intravenous%20Iron%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of chronic kidney disease (CKD) is projected to propel the expansion of the intravenous iron drugs market moving forward. Chronic kidney disease (CKD) signifies the progressive deterioration of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is attributed to escalating rates of diabetes and hypertension, which contribute to kidney damage over time. Intravenous iron drugs aid chronic kidney disease patients by replenishing iron stores, rectifying anemia, and enhancing hemoglobin levels, which in turn improves oxygen transport and lessens the requirement for erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney disease (CKD) is driving the growth of the intravenous iron drugs market.

Intravenous Iron Drugs Market Segment Breakdown: Which Categories Lead On Revenue?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Intravenous Iron Drugs Market Trends Powering Strategic Industry Growth

Leading companies active in the intravenous iron drugs market are prioritizing the creation of novel therapies, such as intravenous (IV) iron replacement therapy, to enhance effectiveness, safety, and patient outcomes. Intravenous (IV) iron replacement therapy functions as a medical procedure that delivers iron directly into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly beneficial for patients who struggle to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical entity specializing in advanced drug development and healthcare provisions, declared that the U.S. Food and Drug Administration (FDA) had sanctioned Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients suffering from heart failure classified as New York Heart Association class II/III, with the aim of boosting exercise capacity. Injectafer is a broadly applied intravenous iron treatment, noted for its rapid replenishment of iron levels in individuals who are intolerant to or do not respond well to oral iron supplements.

Intravenous Iron Drugs Market Leading Players And Competitive Positioning

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

View The Full Intravenous Iron Drugs Market Report:

https://thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Intravenous Iron Drugs Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Intravenous Iron Drugs Market Expansion From $4.21 Billion In 2026 To $6.33 Billion In 2030

The intravenous iron drugs sector has seen swift expansion in recent times. Valued at $3.81 billion in 2025, it is projected to reach $4.22 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. This historical growth has been driven by factors such as the widespread occurrence of iron deficiency anemia, the constraints of oral iron absorption, hospital protocols for managing anemia, rising utilization in dialysis facilities, and the therapeutic efficacy of IV iron treatments.

The intravenous iron drugs market is anticipated to experience substantial expansion over the coming years, with projections indicating a rise to $6.34 billion by 2030, fueled by a compound annual growth rate (CAGR) of 10.7%. This forecasted growth is driven by factors such as the escalating prevalence of chronic conditions, an expanding population undergoing dialysis, a higher incidence of anemia associated with cancer, a growing demand for swift hemoglobin level correction, and the broadening reach of outpatient infusion services. Key trends shaping this period include the growing application of these drugs for managing iron deficiency anemia, an increasing preference for them among patients with chronic kidney disease, a shift away from oral iron supplements toward intravenous alternatives, the introduction of more single-dose iron formulations, and their enhanced use within oncology and gastroenterology fields.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Intravenous Iron Drugs Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising prevalence of chronic kidney disease (CKD) is anticipated to drive the expansion of the intravenous iron drugs market in the coming years. Chronic kidney disease (CKD) is characterized by the progressive decline of kidney function over time, impairing the kidneys’ capacity to adequately remove waste and surplus fluids from the bloodstream. This increase in CKD incidence is largely attributed to the growing rates of diabetes and hypertension, which gradually cause kidney impairment. Intravenous iron medications are used to restore iron levels in CKD patients, correct anemia, and boost hemoglobin levels, thereby improving oxygen delivery and decreasing the reliance on erythropoiesis-stimulating agents. For example, in July 2025, a report from Hamadan University of Medical Sciences, an institution based in Iran, indicated that the global count of newly diagnosed chronic kidney disease cases is expected to reach 25.06 million by 2030. Consequently, the escalating incidence of chronic kidney disease (CKD) is fostering growth in the intravenous iron drugs market.

Intravenous Iron Drugs Market Segment Analysis: What Are The Major Market Categories?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Intravenous Iron Drugs Market Industry Trends: What Changes Are Reshaping Demand?

Key players in the intravenous iron drugs market are concentrating on the creation of cutting-edge treatments, such as intravenous (IV) iron replacement therapy, with the goal of boosting effectiveness, safety, and patient results. This approach involves delivering iron straight into the circulation via an IV infusion, serving as a remedy for iron deficiency and anemia, particularly for individuals who cannot handle or sufficiently absorb oral iron supplements. As an example, Daiichi Sankyo Company Limited, a pharmaceutical entity from Japan focused on pioneering drug development and healthcare services, revealed in June 2023 that the U.S. Food and Drug Administration (FDA) had given the green light to Injectafer (ferric carboxymaltose injection) for managing iron deficiency in adult heart failure patients classified as New York Heart Association class II/III, aiming to boost exercise tolerance. Injectafer stands as a frequently employed intravenous iron treatment, recognized for its swift ability to restore iron levels in patients who either cannot endure or fail to respond effectively to oral iron supplements.

Intravenous Iron Drugs Market Leading Companies Driving Competitive Growth

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Access The Complete Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Intravenous Iron Drugs Market Geographic Distribution And Regional Opportunities

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Intravenous Iron Drugs Market Through 2030?

The market size for intravenous iron drugs has experienced substantial growth in recent years. It is anticipated to increase from $3.81 billion in 2025 to $4.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.8%. Historically, this expansion has been driven by factors such as the widespread occurrence of iron deficiency anemia, the limitations of oral iron absorption, the implementation of hospital-based anemia management protocols, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.

The intravenous iron drugs market is projected for swift expansion in the coming years, reaching $6.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period stems from factors such as an escalating chronic disease burden, an expanding population of dialysis patients, a rise in cancer-related anemia occurrences, the desire for quick hemoglobin restoration, and the broadening availability of outpatient infusion services. Key trends observed in this period encompass the increasing application in managing iron deficiency anemia, its greater uptake among chronic kidney disease patients, a rising preference compared to oral iron treatments, the proliferation of single-dose iron preparations, and enhanced usage within the fields of oncology and gastroenterology.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Primary Factors Are Fueling The Expansion Of The Intravenous Iron Drugs Market?

The expanding prevalence of chronic kidney disease (CKD) is anticipated to fuel the progression of the intravenous iron drugs market in the future. CKD involves a progressive decline in kidney function, preventing the kidneys from efficiently removing waste and excess fluids from the bloodstream. This rising incidence of CKD is linked to increasing cases of diabetes and hypertension, both of which contribute to kidney damage over time. Intravenous iron drugs provide assistance to CKD patients by restoring iron levels, rectifying anemia, and elevating hemoglobin, thereby enhancing oxygen delivery and minimizing the requirement for erythropoiesis-stimulating agents. For example, in July 2025, Hamadan University of Medical Sciences, an Iran-based institution, predicted that the worldwide count of new chronic kidney disease diagnoses would reach 25.06 million by 2030. Consequently, the escalating occurrence of chronic kidney disease (CKD) is propelling the expansion of the intravenous iron drugs market.

What Segment Types Are Included In The Intravenous Iron Drugs Market Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Expected To Shape The Intravenous Iron Drugs Market?

Leading companies operating in the intravenous iron drugs market are concentrating on developing novel therapies, such as intravenous (IV) iron replacement therapy, to enhance their efficacy, safety, and patient outcomes. This medical intervention involves the direct delivery of iron into the bloodstream through an intravenous infusion, primarily used to treat iron deficiency and anemia, especially in patients who cannot tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to enhance exercise capacity. Injectafer is a widely utilized intravenous iron therapy recognized for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Leading Firms Participating In The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Access The Complete Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Region Is The Dominant Market In The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Intravenous Iron Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Intravenous Iron Drugs Market Grow Between 2026 And 2030?

The market size for intravenous iron drugs has seen rapid expansion over recent years. It is forecast to grow from $3.81 billion in 2025 to $4.22 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This historical growth can be ascribed to the high prevalence of iron deficiency anemia, the limitations inherent in oral iron absorption, the adoption of hospital-based anemia management protocols, increased utilization in dialysis centers, and the proven clinical effectiveness of intravenous iron therapies.

The intravenous iron drugs market is projected for substantial expansion in the upcoming years, with its value anticipated to reach $6.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. This expansion during the forecast period is primarily fueled by an increasing burden of chronic diseases, a growing demographic of dialysis patients, a rise in cancer-related anemia occurrences, the preference for swift hemoglobin correction, and the wider availability of outpatient infusion services. Prominent trends observed in this period include an intensified application in managing iron deficiency anemia, increased adoption among chronic kidney disease patients, a developing preference over oral iron therapies, the introduction and expansion of single-dose iron formulations, and higher utilization within oncology and gastroenterology.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Primary Drivers Are Shaping The Intravenous Iron Drugs Market?

The increasing prevalence of chronic kidney disease (CKD) is anticipated to fuel the expansion of the intravenous iron drugs market in the foreseeable future. CKD is characterized by a gradual deterioration of kidney function over time, impeding the kidneys’ capacity to effectively filter waste and excess fluids from the blood. This rise in CKD cases is largely attributed to escalating rates of diabetes and hypertension, conditions known to cause progressive kidney damage. Intravenous iron drugs provide support to chronic kidney disease patients by replenishing iron stores, rectifying anemia, and elevating hemoglobin levels, which in turn enhances oxygen transport and lessens the dependence on erythropoiesis-stimulating agents. For instance, in July 2025, according to Hamadan University of Medical Sciences, a Iran-based university, the global number of newly diagnosed chronic kidney diseases is projected to rise to 25.06 million by 2030. Thus, the rising incidence of chronic kidney disease is a significant driver for the growth of the intravenous iron drugs market.

How Are Different Segments Classified In The Intravenous Iron Drugs Market Segment Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Impacting The Progress Of The Intravenous Iron Drugs Market?

Leading companies within the intravenous iron drugs market are concentrating on developing novel therapies, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical procedure that directly delivers iron into the bloodstream through an intravenous infusion. This treatment addresses iron deficiency and anemia, particularly in patients unable to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for managing iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to boost exercise capacity. Injectafer is a widely used intravenous iron therapy, noted for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Companies Driving Activity In The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Get The Full Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Region Dominates The Intravenous Iron Drugs Market By Market Share?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Intravenous Iron Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Intravenous Iron Drugs Market Across 2026–2030?

The intravenous iron drugs market has witnessed significant expansion recently. This market is expected to expand from $3.81 billion in 2025 to $4.22 billion in 2026, registering a compound annual growth rate (CAGR) of 10.8%. The observed growth in past periods is linked to the widespread incidence of iron deficiency anemia, the inherent limitations of oral iron absorption, the implementation of anemia management protocols in hospitals, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.

The market size for intravenous iron drugs is anticipated to undergo swift expansion in the coming years. This market is projected to attain a value of $6.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. This increase during the forecast period is primarily driven by an escalating burden of chronic diseases, an expanding population of dialysis patients, a rise in cancer-related anemia cases, a preference for quick hemoglobin correction, and the broadening of outpatient infusion services. Significant trends expected during this period include the increased application in managing iron deficiency anemia, a growing acceptance among chronic kidney disease patients, a developing preference over oral iron therapies, the expansion of single-dose iron formulations, and enhanced utilization in oncology and gastroenterology.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Primary Drivers Are Shaping The Development Of The Intravenous Iron Drugs Market?

The increasing prevalence of chronic kidney disease (CKD) is anticipated to stimulate the expansion of the intravenous iron drugs market. CKD is defined as the progressive decline of kidney function over time, hindering the kidneys’ capacity to effectively filter waste products and excess fluids from the blood. This rise in CKD cases stems from the growing rates of diabetes and hypertension, which contribute to kidney damage. Intravenous iron drugs assist chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, thereby enhancing oxygen transport and lessening the reliance on erythropoiesis-stimulating agents. As an illustration, Hamadan University of Medical Sciences, an Iran-based institution, projected in July 2025 that the global figure for newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Thus, the escalating incidence of chronic kidney disease (CKD) is a primary catalyst for the growth of the intravenous iron drugs market.

What Segmentation Levels Are Considered In The Intravenous Iron Drugs Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Trends Are Projected To Affect The Intravenous Iron Drugs Market?

Leading firms within the intravenous iron drugs market are concentrating on creating novel treatments, including intravenous (IV) iron replacement therapy, to enhance effectiveness, security, and results for patients. This therapy involves a medical procedure where iron is administered straight into the bloodstream via an intravenous infusion. It addresses iron deficiency and anemia, particularly in individuals unable to tolerate or properly absorb oral iron supplements. As an example, in June 2023, Daiichi Sankyo Company Limited, a pharmaceutical enterprise from Japan renowned for its focus on advanced drug development and health solutions, disclosed that the U.S. Food and Drug Administration (FDA) had granted approval for Injectafer (ferric carboxymaltose injection). This approval was specifically for managing iron deficiency in adult heart failure patients categorized as New York Heart Association class II/III, aiming to boost their exercise capacity. Injectafer stands as a frequently utilized intravenous iron treatment, recognized for its ability to swiftly restore iron levels in individuals who either cannot tolerate or do not respond effectively to oral iron supplements.

Which Leading Firms Are Contributing To The Growth Of The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Read the full intravenous iron drugs market report here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

How Does The Intravenous Iron Drugs Market Perform Across Major Global Regions?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Intravenous Iron Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the intravenous iron drugs market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Intravenous Iron Drugs Market by the end of 2030?

The intravenous iron drugs market size has experienced rapid growth recently. It is set to expand from $3.81 billion in 2025 to $4.22 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. This historical growth can be credited to the high prevalence of iron deficiency anemia, limitations associated with oral iron absorption, hospital-based anemia management protocols, increased utilization in dialysis centers, and the clinical effectiveness of IV iron therapies.

The market for intravenous iron drugs is anticipated to experience swift expansion over the coming years, reaching a valuation of $6.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This projected growth during the forecast timeframe stems from factors such as an escalating burden of chronic diseases, an expanding demographic of dialysis patients, a rise in anemia cases linked to cancer, a preference for quick hemoglobin restoration, and the broadening availability of outpatient infusion services. Key trends expected within this period encompass the increased application in managing iron deficiency anemia, greater uptake among individuals with chronic kidney disease, an escalating preference over traditional oral iron treatments, the proliferation of single-dose iron preparations, and enhanced usage across the fields of oncology and gastroenterology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Drivers Are Shaping Future Opportunities In The Intravenous Iron Drugs Market?

The increasing occurrence of chronic kidney disease (CKD) is anticipated to drive expansion in the intravenous iron drugs market moving ahead. CKD describes a progressive decline in kidney function where the kidneys gradually lose their capacity to efficiently remove waste products and surplus fluids from the bloodstream. This rise in CKD cases stems from the escalating prevalence of diabetes and hypertension, both of which contribute to long-term kidney damage. Intravenous iron medications assist CKD patients by restoring iron reserves, correcting anemia, and boosting hemoglobin concentrations, thereby improving oxygen delivery and decreasing reliance on erythropoiesis-stimulating agents. For example, data from July 2025 by Hamadan University of Medical Sciences, an Iran-based university, indicates a global projection of newly diagnosed chronic kidney diseases to reach 25.06 million by 2030. Consequently, the expanding incidence of chronic kidney disease (CKD) is fueling the development of the intravenous iron drugs market.

Which Segments Are Gaining Traction In The Intravenous Iron Drugs Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Trends Are Guiding The Evolution Of The Intravenous Iron Drugs Market?

Leading companies in the intravenous iron drugs market are concentrating on developing novel treatments, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy is a medical intervention that delivers iron directly into the bloodstream through an intravenous infusion. This therapy addresses iron deficiency and anemia, especially for patients unable to tolerate or adequately absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to improve exercise capacity. Injectafer is a widely used intravenous iron therapy recognized for rapidly replenishing iron levels in patients who cannot tolerate or do not respond well to oral iron supplements.

Who Are The Primary Competitors In The Global Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are Pharmacosmos A/S, American Regent Inc., Fresenius SE & Co. KGaA, Sandoz Group AG, Hikma Pharmaceuticals plc, Rockwell Medical Inc., Daiichi Sankyo Company Ltd., CSL Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Limited, Vifor Pharma Management Ltd., Galenica Ltd., Aspen Pharmacare Holdings Limited, Lupin Limited, Aurobindo Pharma Limited, Jiangsu Hengrui Pharmaceutical Co. Ltd., Kissei Pharmaceutical Co. Ltd., Nanjing Hicin Pharmaceutical Co. Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Intravenous Iron Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Hemochromatosis Iron Overload Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hemochromatosis-iron-overload-disease-treatment-global-market-report

Intravenous Solutions Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anthrax vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Anthrax Vaccine Market And What Value Is Projected For 2029?

The intravenous iron drugs market size has seen rapid expansion in recent years. This market is set to increase from $3.44 billion in 2024 to $3.81 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.6%. The historical growth of the market can be linked to the increasing prevalence of iron deficiency anemia, the rising prevalence of chronic diseases, growing healthcare spending, an aging population, and a higher incidence of target illnesses.

The intravenous iron drugs market is anticipated to experience substantial expansion in the coming years, with its size projected to reach $5.73 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.8%. This growth during the forecast period can be attributed to several factors including government initiatives, ongoing research and development in the field of IV iron drugs, a rising demand for intravenous iron medicines, an increasing number of research and development activities, and enhancements in administration and formulation. Key trends expected in the forecast period involve advanced intravenous iron therapies, continued advancements in drug development, a move towards more convenient IV iron treatments, strategic collaborations, partnerships, and acquisitions, alongside innovations in novel drug delivery systems.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Factors Are Boosting The Anthrax Vaccine Market?

The increasing occurrence of chronic kidney disease (CKD) is projected to boost the expansion of the intravenous iron drugs market moving ahead. Chronic kidney disease (CKD) describes a progressive decline in kidney function over time, resulting in the kidneys losing their capacity to properly remove waste and surplus fluids from the bloodstream. This rise in chronic kidney disease (CKD) cases stems from higher rates of diabetes and hypertension, conditions that progressively harm the kidneys. Intravenous iron drugs assist individuals with chronic kidney disease by restoring iron reserves, correcting anemia, and elevating hemoglobin levels, thereby facilitating oxygen transport and lessening the reliance on erythropoiesis-stimulating agents. For example, data from June 2024 by the Australian Institute of Health and Welfare, an Australia-based government entity, revealed that chronic kidney disease (CKD) death rates increased by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD accounted for approximately 22,000 deaths in Australia, representing 11% of all mortalities. Consequently, the increasing prevalence of chronic kidney disease (CKD) is fueling the expansion of the intravenous iron drugs market.

What Are The Core Segmentation Criteria In The Anthrax Vaccine Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Emerging Trends Are Reshaping The Anthrax Vaccine Market Landscape?

Leading companies in the intravenous iron drugs market are prioritizing the development of innovative therapies, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy serves as a medical intervention that directly administers iron into the bloodstream through an intravenous infusion. This treatment is employed for iron deficiency and anemia, especially in patients who are unable to tolerate or adequately absorb oral iron supplements. For example, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical entity specializing in innovative drug development and healthcare solutions, announced that the U.S. Food and Drug Administration (FDA) had given its approval for Injectafer (ferric carboxymaltose injection) for managing iron deficiency in adult patients suffering from heart failure classified as New York Heart Association class II/III, aiming to improve their exercise capacity. Injectafer is a widely recognized intravenous iron therapy known for its effectiveness in quickly replenishing iron levels in patients who either cannot tolerate oral iron supplements or do not respond well to them.

Which Players Are Shaping The Competitive Landscape Of The Anthrax VaccineXX Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

What Regional Trends Are Shaping Growth In The Anthrax Vaccine Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2025, By The Business Research Company

Iron Ore Pellets Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-ore-pellets-global-market-report

Iron And Steel Mills And Ferroalloy Market 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-mills-and-ferroalloy-market

Iron And Steel Casting Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-casting-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model